title: Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture.
abstract: The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.
authors.affiliation: Department of Chemistry, University of Bremen, Federal Republic of Germany.
authors.forename: D
authors.initials: D
authors.lastname: Gabel
authors.forename: D
authors.initials: D
authors.lastname: Preusse
authors.forename: D
authors.initials: D
authors.lastname: Haritz
authors.forename: F
authors.initials: F
authors.lastname: Grochulla
authors.forename: K
authors.initials: K
authors.lastname: Haselsberger
authors.forename: H
authors.initials: H
authors.lastname: Fankhauser
authors.forename: C
authors.initials: C
authors.lastname: Ceberg
authors.forename: H D
authors.initials: HD
authors.lastname: Peters
authors.forename: U
authors.initials: U
authors.lastname: Klotz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001894:Borohydrides / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D005260:Female; D005910:Glioma / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D001894:Borohydrides